Fluoroquinolones and Risk for Methicillin-Resistant Staphylococcus aureus, Canada

Receipt of fluoroquinolones was the predominant risk factor for Clostridium difficile–associated disease (CDAD) during an epidemic in Quebec, Canada. To determine the role of antimicrobial drugs in facilitating healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA) colonization and...

Full description

Bibliographic Details
Main Authors: Louiselle LeBlanc, Jacques Pépin, Krystel Toulouse, Marie-France Ouellette, Marie-Andrée Coulombe, Marie-Pier Corriveau, Marie-Eve Alary
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2006-09-01
Series:Emerging Infectious Diseases
Subjects:
Online Access:https://wwwnc.cdc.gov/eid/article/12/9/06-0397_article
_version_ 1819011651332997120
author Louiselle LeBlanc
Jacques Pépin
Krystel Toulouse
Marie-France Ouellette
Marie-Andrée Coulombe
Marie-Pier Corriveau
Marie-Eve Alary
author_facet Louiselle LeBlanc
Jacques Pépin
Krystel Toulouse
Marie-France Ouellette
Marie-Andrée Coulombe
Marie-Pier Corriveau
Marie-Eve Alary
author_sort Louiselle LeBlanc
collection DOAJ
description Receipt of fluoroquinolones was the predominant risk factor for Clostridium difficile–associated disease (CDAD) during an epidemic in Quebec, Canada. To determine the role of antimicrobial drugs in facilitating healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA) colonization and infection and to compare this role with their effects on methicillin-susceptible S. aureus infection and CDAD, we conducted a retrospective cohort study of patients in a Quebec hospital. For 7,371 episodes of care, data were collected on risk factors, including receipt of antimicrobial drugs. Crude and adjusted hazard ratios (AHR) were calculated by Cox regression. Of 150 episodes of MRSA colonization and 23 of MRSA infection, fluoroquinolones were the only antimicrobials that increased risk for colonization (AHR 2.57, 95% confidence interval [CI] 1.84–3.60) and infection (AHR 2.49, 95% CI 1.02–6.07). Effect of antimicrobial drugs on MRSA colonization and infection was similar to effect on CDAD and should be considered when selecting antimicrobial drugs to treat common infections.
first_indexed 2024-12-21T01:31:33Z
format Article
id doaj.art-5f46f4eee2be4d769236340a3e251378
institution Directory Open Access Journal
issn 1080-6040
1080-6059
language English
last_indexed 2024-12-21T01:31:33Z
publishDate 2006-09-01
publisher Centers for Disease Control and Prevention
record_format Article
series Emerging Infectious Diseases
spelling doaj.art-5f46f4eee2be4d769236340a3e2513782022-12-21T19:20:22ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592006-09-011291398140510.3201/eid1209.060397Fluoroquinolones and Risk for Methicillin-Resistant Staphylococcus aureus, CanadaLouiselle LeBlancJacques PépinKrystel ToulouseMarie-France OuelletteMarie-Andrée CoulombeMarie-Pier CorriveauMarie-Eve AlaryReceipt of fluoroquinolones was the predominant risk factor for Clostridium difficile–associated disease (CDAD) during an epidemic in Quebec, Canada. To determine the role of antimicrobial drugs in facilitating healthcare-associated methicillin-resistant Staphylococcus aureus (MRSA) colonization and infection and to compare this role with their effects on methicillin-susceptible S. aureus infection and CDAD, we conducted a retrospective cohort study of patients in a Quebec hospital. For 7,371 episodes of care, data were collected on risk factors, including receipt of antimicrobial drugs. Crude and adjusted hazard ratios (AHR) were calculated by Cox regression. Of 150 episodes of MRSA colonization and 23 of MRSA infection, fluoroquinolones were the only antimicrobials that increased risk for colonization (AHR 2.57, 95% confidence interval [CI] 1.84–3.60) and infection (AHR 2.49, 95% CI 1.02–6.07). Effect of antimicrobial drugs on MRSA colonization and infection was similar to effect on CDAD and should be considered when selecting antimicrobial drugs to treat common infections.https://wwwnc.cdc.gov/eid/article/12/9/06-0397_articlemethicillin-resistant Staphylococcus aureusmethicillin-susceptible Staphylococcus aureusfluoroquinolonesCanadaresearch
spellingShingle Louiselle LeBlanc
Jacques Pépin
Krystel Toulouse
Marie-France Ouellette
Marie-Andrée Coulombe
Marie-Pier Corriveau
Marie-Eve Alary
Fluoroquinolones and Risk for Methicillin-Resistant Staphylococcus aureus, Canada
Emerging Infectious Diseases
methicillin-resistant Staphylococcus aureus
methicillin-susceptible Staphylococcus aureus
fluoroquinolones
Canada
research
title Fluoroquinolones and Risk for Methicillin-Resistant Staphylococcus aureus, Canada
title_full Fluoroquinolones and Risk for Methicillin-Resistant Staphylococcus aureus, Canada
title_fullStr Fluoroquinolones and Risk for Methicillin-Resistant Staphylococcus aureus, Canada
title_full_unstemmed Fluoroquinolones and Risk for Methicillin-Resistant Staphylococcus aureus, Canada
title_short Fluoroquinolones and Risk for Methicillin-Resistant Staphylococcus aureus, Canada
title_sort fluoroquinolones and risk for methicillin resistant staphylococcus aureus canada
topic methicillin-resistant Staphylococcus aureus
methicillin-susceptible Staphylococcus aureus
fluoroquinolones
Canada
research
url https://wwwnc.cdc.gov/eid/article/12/9/06-0397_article
work_keys_str_mv AT louiselleleblanc fluoroquinolonesandriskformethicillinresistantstaphylococcusaureuscanada
AT jacquespepin fluoroquinolonesandriskformethicillinresistantstaphylococcusaureuscanada
AT krysteltoulouse fluoroquinolonesandriskformethicillinresistantstaphylococcusaureuscanada
AT mariefranceouellette fluoroquinolonesandriskformethicillinresistantstaphylococcusaureuscanada
AT marieandreecoulombe fluoroquinolonesandriskformethicillinresistantstaphylococcusaureuscanada
AT mariepiercorriveau fluoroquinolonesandriskformethicillinresistantstaphylococcusaureuscanada
AT marieevealary fluoroquinolonesandriskformethicillinresistantstaphylococcusaureuscanada